

ART 34 AMDT

Amended claims (International Phase)

1. An adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, characterised in that the metallic salt particle is substantially free of other antigen and in that the immunostimulant is not a saponin derived from the bark of *Quillaja Saponaria* Molina.
2. An adjuvant composition as claimed in claim 1, wherein the metallic salt particle is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or beryllium.
3. An adjuvant composition as claimed in claims 1 or 2, wherein the metallic salt is a phosphate or hydroxide.
4. An adjuvant composition as claimed in any one of claims 1 to 3, wherein the metallic salt is aluminium hydroxide or aluminium phosphate.
5. An adjuvant composition as claimed in any one of claims 1 to 4, wherein the immunostimulant is monophosphoryl lipid A or a derivative thereof.
6. An adjuvant composition as claimed in claim 5, wherein the derivative of monophosphoryl lipid A is 3-de-O-acylated monophosphoryl lipid A.
7. An adjuvant composition as claimed in any one of claims 1 to 4, wherein the immunostimulant is CpG containing oligonucleotide.
8. A process for the manufacture of a vaccine composition comprising the admixture of a) an adjuvant composition comprising an immunostimulant adsorbed onto a metallic salt particle, characterised in that the metallic salt particle is substantially free of other antigen, and b) an antigen.
9. A process for the manufacture of a vaccine composition as claimed in claim 8, characterised in that the antigen is adsorbed onto a metallic salt particle.
10. A process as claimed in any one of claims 8 or 9, wherein the antigen is selected from the group comprising: antigens derived from Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, IgE peptides,

AMENDED SHEET

09807657.04.1601

Herp1, pollen related antigens; or Tumor associated antigens (TAA), MAGE, BAGE, CAGE, MUC-1, Her-2 neu, LHRH(GnRH), CEA, PSA, KSA, or PRAME.

11. A vaccine composition comprising an adjuvant composition according to claims 1 to 7, additionally comprising an antigen.
12. A vaccine produced according to the process claimed in any one of claims 8 to 10.
13. A vaccine comprising a saponin adsorbed onto a metallic salt particle wherein the vaccine comprises an antigen, characterised in that the metallic salt particle is substantially free of other antigen.
14. A vaccine according to claim 13, wherein the saponin is QS21.
15. A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle.
16. A vaccine composition comprising two major populations of complexes, a first complex comprising (a) an immunostimulant adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of antigen; and a second complex comprising (b) antigen adsorbed onto a metallic salt particle, characterised in that said metallic salt particle is substantially free of monophosphoryl lipid A, or derivative thereof.
17. A vaccine composition as claimed in claims 15 or 16, wherein the metallic salt present in the first and second complexes are identical.
18. A vaccine composition as claimed in any one of claims 15 to 17, wherein the second complex comprises a plurality of sub-complexes, each sub-complex comprising a different antigen adsorbed onto a metallic particle.
19. A vaccine composition as claimed in any one of claims 13 to 18, wherein the metallic salt is a salt of aluminium, zinc, calcium, cerium, chromium, iron, or beryllium.
20. A vaccine composition as claimed in claim 19 wherein the metallic salt is a phosphate or hydroxide.
21. A vaccine composition as claimed in claim 20 wherein the metallic salt is aluminium hydroxide or aluminium phosphate.

AMENDED SHEET

ART 34 AMDT

22. A vaccine composition as claimed in any one of claims 11-12, and 15 to 21, wherein the immunostimulant is 3-de-O-acylated monophosphoryl lipid A.
23. A vaccine composition as claimed in any one of claims 11 to 18, wherein the immunostimulant is CpG.
24. A vaccine composition as claimed in any one of claims 11 to 21, wherein the antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma, standworth decapeptide, Der p1, pollen related antigens; or cancer associated antigens, MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LHRH(GnRH), CEA, PSA, tyrosinase, Survivin, K5A, or PRAME.
25. A vaccine composition as claimed in claim 24, wherein the antigen is a combination of Hepatitis A antigen and Hepatitis B antigen.
26. A vaccine composition as claimed in claim 24, wherein the plasmodium antigen is one or more antigens selected from the following group: RTS,S and TRAP.
28. A vaccine composition as claimed in claim 24 for use in medicine.
29. Use of vaccine composition as claimed in claim 24, for the manufacture of an medicament suitable for the prophylaxis or the treatment of viral, bacterial, parasitic infections, allergy, or cancer.
30. A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to claim 24.
31. A kit comprising two containers, one container having monophosphoryl lipid A, or derivative thereof, adsorbed onto a metallic salt; and the second container having antigen adsorbed onto a metallic salt.

Add B¹

Add D⁵

AMENDED SHEET